Dr. Robert Gut joined uniQure as Chief Medical Officer in August 2018. Dr. Robert Gut has served as a member of our Board since June 2018. Dr. Gut has 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas.
Dr. Gut most recently served as Chief Medical Officer of Versartis, Inc. until its merger with Aravive Biologics in June 2018. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc., where he headed the company's U.S. Biopharm Medical organization with leading products in hemophilia, including NovoSeven® (Factor VIIa), NovoEight® (Factor VIII), Tretten® (Factor XIII) and Factor IX. Dr. Gut's contributions helped achieve nine different FDA approvals and the successful launches of those products. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research.
Dr. Gut is responsible for leading all clinical development, medical affairs and related functions at uniQure.
Dr. Gut received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.
What is Robert Gut's net worth?
The estimated net worth of Robert Gut is at least $185,772.26 as of January 26th, 2021. Mr. Gut owns 40,919 shares of uniQure stock worth more than $185,772 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Gut may own. Learn More about Robert Gut's net worth.
How do I contact Robert Gut?
The corporate mailing address for Mr. Gut and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Robert Gut's contact information.
Has Robert Gut been buying or selling shares of uniQure?
Robert Gut has not been actively trading shares of uniQure over the course of the past ninety days. Most recently, Robert Gut sold 2,348 shares of the business's stock in a transaction on Wednesday, January 26th. The shares were sold at an average price of $18.12, for a transaction totalling $42,545.76. Learn More on Robert Gut's trading history.
Who are uniQure's active insiders?
Are insiders buying or selling shares of uniQure?
In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 81,031 shares worth more than $683,268.05. The most recent insider tranaction occured on February, 26th when COO Pierre Caloz sold 9,455 shares worth more than $61,173.85. Insiders at uniQure own 4.1% of the company.
Learn More about insider trades at uniQure. Information on this page was last updated on 2/26/2024.
